Abac’s precision platform

How Abac’s pathogen-specific approach could reduce emergence of antibiotic resistance

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics.

The company’s PasNas platform uses phenotypic and in vitro assays to screen chemical libraries and identify pathogen-specific antibiotics for multidrug resistant microbes. According to CSO Domingo Gargallo-Viola, PasNas can identify candidates for any infectious microbial

Read the full 585 word article

User Sign In